Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma - PubMed
14 hours ago
- #immunotherapy
- #ovarian cancer
- #bispecific antibody
- ARC101 is a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma.
- CLDN6 is an oncofetal tight junction protein with minimal expression in healthy tissues but upregulated in ovarian malignancies.
- ARC101 features a naturally derived CLDN6 binder with no cross-reactivity to CLDN9 or other human membrane proteins.
- The novel conformational CD3 binder in ARC101 enables potent T cell-mediated cytotoxicity against CLDN6-expressing tumor cells.
- ARC101 demonstrated a favorable pharmacokinetic profile, low immunostimulatory responses, and robust biophysical properties.
- ARC101 is a differentiated, CLDN6-specific bispecific immunotherapy with exceptional tumor selectivity and optimized T cell activity.